



Dedicated To Life

June 3, 2022

BSE Limited

1st Floor,
P J Towers,
Dalal Street,
Mumbai-400001

Code: 532321

National Stock Exchange of India Limited

Exchange Plaza, 5th Floor,
Plot No. C/1, G Block,
Bandra-Kurla Complex, Bandra (East)
Mumbai-400051

Code: Zyduslife

Sub.: **Half yearly disclosure of related party transactions**

Ref.: **Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

Dear Sir,

Pursuant to the provisions of regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the details of Related Party Transactions on for the half year ended on March 31, 2022, in the format prescribed by SEBI.

Please find the same in order.

Thanking you,

Yours faithfully,

For, **ZYDUS LIFESCIENCES LIMITED**
(Formerly known as Cadila Healthcare Limited)

DHAVAL N. SONI
COMPANY SECRETARY

Encl.: As above



Zydus Lifesciences Limited [Formerly Known as Cadila Healthcare Limited]
Disclosure of related party transactions for the half year/ six months ended March 31, 2022

Amount in INR Million except stated otherwise

Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, intercorporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.

S. No.	Details of the party entering into the transaction		Details of the counterparty			Type of Related Party Transaction	Value of the related party transaction as approved by the audit committee	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financials indebtedness is incurred to make or give loans/ investments			Details of loans/ investments				
	Name	PAN [Refer note-1]	Name	PAN [Refer note-1]	Relationship of the counterparty with the listed entity or its subsidiary				Opening balance	Closing balance	Nature of indebtedness [Loans/ issuance of debt/ any other]	Cost of borrowed funds for the listed entity	Tenure	Nature [Loans/ Investments]	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose of the fund utilisation
89	Zydus Lifesciences Limited		Mr. Bhadrash K. Shah		Key Managerial Personnel	Director Sitting Fees and Commission to non executive directors	Refer Note 4	3										
90	Zydus Lifesciences Limited		Dr. Sharvil P. Patel		Key Managerial Personnel	Remuneration to Key Managerial Personnel	Refer Note 4	70										
91	Zydus Lifesciences Limited		Mr. Ganesh N. Nayak		Key Managerial Personnel	Remuneration to Key Managerial Personnel	Refer Note 4	74										
92	Zydus Lifesciences Limited		Mr. Nitin D. Parekh		Key Managerial Personnel	Remuneration to Key Managerial Personnel	Refer Note 4	33										
93	Zydus Lifesciences Limited		Mr. Dhaval N. Soni		Key Managerial Personnel	Remuneration to Key Managerial Personnel	Refer Note 4	1										
94	Zydus Lifesciences Limited		Zydus Worldwide DMCC		Subsidiary Company	Loans given	Refer Note 4	1,506			N.A	N.A	N.A	Loan	USD LIBOR + 50 bps	3 Years	Unsecured	Business purpose
95	Zydus Lifesciences Limited		Zydus VTEC Limited		Subsidiary Company	Loans repaid (received by the Company)	N.A.	2,950										
96	Zydus Lifesciences Limited		Zydus International Private Limited		Subsidiary Company	Interest Income	N.A.	11										
97	Zydus Lifesciences Limited		Zydus Worldwide DMCC		Subsidiary Company	Interest Income	N.A.	21										
98	Zydus Lifesciences Limited		Dialforhealth Unity Limited		Subsidiary Company	Interest Income	N.A.	0										
99	Zydus Lifesciences Limited		Bayer Zydus Pharma Private Limited		Joint Ventures	Interest Income	N.A.	1										
100	Zydus Lifesciences Limited		Zydus Pharmaceuticals (USA) Inc.		Subsidiary Company	Interest Income	N.A.	43										
101	Zydus Lifesciences Limited		Zydus VTEC Limited		Subsidiary Company	Interest Income	N.A.	25										
102	Zydus Lifesciences Limited		Zydus Pharmaceuticals Limited		Subsidiary Company	Interest Income	N.A.	0										
103	Zydus Lifesciences Limited		Zydus Healthcare Limited		Subsidiary Company	Interest Expense	N.A.	39										
104	Zydus Lifesciences Limited		Zydus Healthcare S.A. (Pty) Ltd		Subsidiary Company	Outstanding Payables - Other than loans	N.A.		114	114								
105	Zydus Lifesciences Limited		Zydus Pharmaceuticals (USA) Inc.		Subsidiary Company	Outstanding Payables - Other than loans	N.A.		1,082	447								
106	Zydus Lifesciences Limited		Nesher Pharmaceuticals (USA) LLC		Subsidiary Company	Outstanding Payables - Other than loans	N.A.		3	48								
107	Zydus Lifesciences Limited		Zydus Pharmaceuticals Mexico SA De CV		Subsidiary Company	Outstanding Payables - Other than loans	N.A.		20	8								

Zydus Lifesciences Limited [Formerly Known as Cadila Healthcare Limited]
Disclosure of related party transactions for the half year/ six months ended March 31, 2022

Amount in INR Million except stated otherwise

Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, intercorporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.

S. No.	Details of the party entering into the transaction		Details of the counterparty			Type of Related Party Transaction	Value of the related party transaction as approved by the audit committee	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financials indebtedness is incurred to make or give loans/ investments			Details of loans/ investments			
	Name	PAN [Refer note-1]	Name	PAN [Refer note-1]	Relationship of the counterparty with the listed entity or its subsidiary				Opening balance	Closing balance	Nature of indebtedness [Loans/ issuance of debt/ any other]	Cost of borrowed funds for the listed entity	Tenure	Nature [Loans/ Investments]	Interest Rate (%)	Tenure	Secured/ Unsecured
108	Zydus Lifesciences Limited		Zydus France, SAS		Subsidiary Company	Outstanding Payables - Other than loans	N.A.		169	128							
109	Zydus Lifesciences Limited		Cadmach Machinery Company Private Limited		Enterprises significantly influenced by Directors and/ or their relatives	Outstanding Payables - Other than loans	N.A.		0	1							
110	Zydus Lifesciences Limited		Zydus Hospira Oncology Private Limited		Joint Ventures	Outstanding Payables - Other than loans	N.A.		-	1							
111	Zydus Lifesciences Limited		Sentynl Therapeutics Inc.		Subsidiary Company	Outstanding Payables - Other than loans	N.A.		43	21							
112	Zydus Lifesciences Limited		German Remedies Pharma Private Limited		Subsidiary Company	Outstanding Payables - Other than loans	N.A.		-	0							
113	Zydus Lifesciences Limited		Zydus Wellness Products Limited		Subsidiary Company	Outstanding Payables - Other than loans	N.A.		0	1							
114	Zydus Lifesciences Limited		Viona Pharmaceuticals INC		Subsidiary Company	Outstanding Payables - Other than loans	N.A.		161	16							
115	Zydus Lifesciences Limited		Oneiro Chemicals Private Limited		Enterprises significantly influenced by Directors and/ or their relatives	Outstanding Payables - Other than loans	N.A.		26	64							
116	Zydus Lifesciences Limited		Zydus VTEC Limited		Subsidiary Company	Outstanding Payables - Other than loans	N.A.		9	685							
117	Zydus Lifesciences Limited		Recon Pharmaceuticals and Investments		Subsidiary Company	Outstanding Payables - Other than loans	N.A.		-	11							
118	Zydus Lifesciences Limited		Zydus Healthcare Limited		Subsidiary Company	Outstanding Payables - Other than loans	N.A.		186	399							
119	Zydus Lifesciences Limited		Zydus Hospitals (Vadodara) Private Limited		Enterprises significantly influenced by Directors and/ or their relatives	Outstanding Payables - Other than loans	N.A.		0	0							
120	Zydus Lifesciences Limited		Zydus Hospitals and Healthcare Research Private Limited		Enterprises significantly influenced by Directors and/ or their relatives	Outstanding Payables - Other than loans	N.A.		0	10							

Zydus Lifesciences Limited [Formerly Known as Cadila Healthcare Limited]
Disclosure of related party transactions for the half year/ six months ended March 31, 2022

Amount in INR Million except stated otherwise

Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, intercorporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.

S. No.	Details of the party entering into the transaction		Details of the counterparty			Type of Related Party Transaction	Value of the related party transaction as approved by the audit committee	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financials indebtedness is incurred to make or give loans/ investments			Details of loans/ investments			
	Name	PAN [Refer note-1]	Name	PAN [Refer note-1]	Relationship of the counterparty with the listed entity or its subsidiary				Opening balance	Closing balance	Nature of indebtedness [Loans/ issuance of debt/ any other]	Cost of borrowed funds for the listed entity	Tenure	Nature [Loans/ Investments]	Interest Rate (%)	Tenure	Secured/ Unsecured
136	Zydus Lifesciences Limited		Viona Pharmaceuticals INC		Subsidiary Company	Outstanding Receivables - Other than loans	N.A.		373	225							
137	Zydus Lifesciences Limited		Etna Biotech S.R.L.		Subsidiary Company	Outstanding Receivables - Other than loans	N.A.		76	76							
138	Zydus Lifesciences Limited		Zydus France, SAS		Subsidiary Company	Outstanding Receivables - Other than loans	N.A.		550	401							
139	Zydus Lifesciences Limited		Zydus VTEC Limited		Subsidiary Company	Outstanding Receivables - Other than loans	N.A.		245	34							
140	Zydus Lifesciences Limited		Zydus International Private Limited		Subsidiary Company	Outstanding Receivables - Loans	N.A.		3,235	3,314							
141	Zydus Lifesciences Limited		Dialforhealth Unity Limited		Subsidiary Company	Outstanding Receivables - Loans	N.A.		2	2							
142	Zydus Lifesciences Limited		Zydus Worldwide DMCC		Subsidiary Company	Outstanding Receivables - Other than loans	N.A.		1,452	1,145							
143	Zydus Lifesciences Limited		Zydus Pharmaceuticals (USA) Inc.		Subsidiary Company	Outstanding Receivables - Other than loans	N.A.		12,046	14,214							
144	Zydus Lifesciences Limited		Zydus Healthcare S.A. (Pty) Ltd		Subsidiary Company	Outstanding Receivables - Other than loans	N.A.		591	457							
145	Zydus Lifesciences Limited		Laboratorios Combix S.L.		Subsidiary Company	Outstanding Receivables - Other than loans	N.A.		272	97							
146	Zydus Lifesciences Limited		Bayer Zydus Pharma Private Limited		Joint Ventures	Outstanding Receivables - Other than loans	N.A.		56	14							
147	Zydus Lifesciences Limited		Zydus Healthcare Philippines Inc.		Subsidiary Company	Outstanding Receivables - Other than loans	N.A.		102	187							
148	Zydus Lifesciences Limited		German Remedies Pharma Private Limited		Subsidiary Company	Outstanding Receivables - Other than loans	N.A.		1	5							
149	Zydus Lifesciences Limited		Zydus International Private Limited		Subsidiary Company	Outstanding Receivables - Other than loans	N.A.		28	48							
150	Zydus Lifesciences Limited		Zydus Therapeutics INC		Subsidiary Company	Outstanding Receivables - Other than loans	N.A.		-	10							
151	Zydus Lifesciences Limited		Alidac Healthcare (Myanmar) Limited		Subsidiary Company	Outstanding Receivables - Other than loans	N.A.		51	19							
152	Zydus Lifesciences Limited		Zydus Pharmaceuticals (USA) Inc.		Subsidiary Company	Outstanding Receivables - Loans	N.A.		12,616	12,881							

Zydus Lifesciences Limited [Formerly Known as Cadila Healthcare Limited]
Disclosure of related party transactions for the half year/ six months ended March 31, 2022

Amount in INR Million except stated otherwise

Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, intercorporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.

S. No.	Details of the party entering into the transaction		Details of the counterparty			Type of Related Party Transaction	Value of the related party transaction as approved by the audit committee	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financials indebtedness is incurred to make or give loans/ investments			Details of loans/ investments				
	Name	PAN [Refer note-1]	Name	PAN [Refer note-1]	Relationship of the counterparty with the listed entity or its subsidiary				Opening balance	Closing balance	Nature of indebtedness [Loans/ issuance of debt/ any other]	Cost of borrowed funds for the listed entity	Tenure	Nature [Loans/ Investments]	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose of the fund utilisation
251	Zydus Healthcare Limited		Cadmach Machinery Company Private Limited		Enterprises significantly influenced by Directors and/ or their relatives	Purchase of Services	Refer Note 3	0										
252	Zydus Healthcare Limited		Zydus Wellness Limited		Subsidiary Company	Sale of Goods	Refer Note 3	0										
253	Zydus Healthcare Limited		Zydus Wellness Products Limited		Subsidiary Company	Sale of Goods	Refer Note 3	0										
254	Zydus Healthcare Limited		German Remedies Pharma Private Limited		Subsidiary Company	Sale of Goods	Refer Note 3	17										
255	Zydus Healthcare Limited		Bayer Zydus Pharma Private Limited		Joint Ventures	Sale of Goods	Refer Note 3	17										
256	Zydus Healthcare Limited		Zydus Hospitals and Healthcare Research Private Limited		Enterprises significantly influenced by Directors and/ or their relatives	Sale of Goods	Refer Note 3	7										
257	Zydus Healthcare Limited		Zydus Wellness Products Limited		Subsidiary Company	Sale of Services	Refer Note 3	7										
258	Zydus Healthcare Limited		Dr. Sharvil P. Patel		Key Managerial Personnel	Director Sitting Fees and Commission to non executive directors	Refer Note 4	0										
259	Zydus Healthcare Limited		Ms. Dharmishta N. Raval		Key Managerial Personnel	Director Sitting Fees and Commission to non executive directors	Refer Note 4	1										
260	Zydus Healthcare Limited		Mr. Nitin D. Parekh		Key Managerial Personnel	Director Sitting Fees and Commission to non executive directors	Refer Note 4	0										
261	Zydus Healthcare Limited		Zydus Wellness Products Limited		Subsidiary Company	Interest Income	N.A.	90										
262	Zydus Healthcare Limited		Zydus Pharmaceuticals Limited		Subsidiary Company	Interest Income	N.A.	62										
263	Zydus Healthcare Limited		Zydus VTEC Limited		Subsidiary Company	Interest Income	N.A.	21										
264	Zydus Healthcare Limited		Zydus Wellness Products Limited		Subsidiary Company	Loans given	Refer Note 4	380			N.A	N.A	N.A	Loan	1 year GSEC + 50 bps	1 Year	Unsecured	Working Capital
265	Zydus Healthcare Limited		Zydus Pharmaceuticals Limited		Subsidiary Company	Loans given	Refer Note 4	1,106			N.A	N.A	N.A	Loan	1 year GSEC + 50 bps	5 Years	Unsecured	Business purpose
266	Zydus Healthcare Limited		Zydus VTEC Limited		Subsidiary Company	Loans given	Refer Note 4	1,950			N.A	N.A	N.A	Loan	1 year GSEC + 50 bps	3 Years	Unsecured	Business purpose

Zydu Lifesciences Limited [Formerly Known as Cadila Healthcare Limited]
Disclosure of related party transactions for the half year/ six months ended March 31, 2022

Amount in INR Million except stated otherwise

Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, intercorporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.

S. No.	Details of the party entering into the transaction		Details of the counterparty			Type of Related Party Transaction	Value of the related party transaction as approved by the audit committee	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financials indebtedness is incurred to make or give loans/ investments			Details of loans/ investments				
	Name	PAN [Refer note-1]	Name	PAN [Refer note-1]	Relationship of the counterparty with the listed entity or its subsidiary				Opening balance	Closing balance	Nature of indebtedness [Loans/ issuance of debt/ any other]	Cost of borrowed funds for the listed entity	Tenure	Nature [Loans/ Investments]	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose of the fund utilisation
301	Zydu Pharmaceuticals (USA) Inc.		Viona Pharmaceuticals INC		Subsidiary Company	Reimbursement of Expenses Recovered	N.A.	2										
302	Zydu Pharmaceuticals (USA) Inc.		Zydu Therapeutics INC		Subsidiary Company	Reimbursement of Expenses Paid	N.A.	0										
303	Zydu Pharmaceuticals (USA) Inc.		Nesher Pharmaceuticals (USA) LLC		Subsidiary Company	Interest Income	N.A.	15										
304	Zydu Pharmaceuticals (USA) Inc.		Sentynl Therapeutics Inc.		Subsidiary Company	Loans given	N.A.	4,397			N.A	N.A	N.A	Loan	SOFR + 55 bps	3 Years	Unsecured	Business loan
305	Zydu Pharmaceuticals (USA) Inc.		Sentynl Therapeutics Inc.		Subsidiary Company	Interest Income	N.A.	9										
306	Zydu Pharmaceuticals (USA) Inc.		Zydu Noveltech Inc.		Subsidiary Company	Interest Income	N.A.	1										
307	Zydu Pharmaceuticals (USA) Inc.		Viona Pharmaceuticals INC		Subsidiary Company	Loans given	N.A.	186			N.A	N.A	N.A	Loan	USD LIBOR + 54 bps	3 Years	Unsecured	Business loan
308	Zydu Pharmaceuticals (USA) Inc.		Viona Pharmaceuticals INC		Subsidiary Company	Interest Income	N.A.	1										
309	Zydu Pharmaceuticals (USA) Inc.		Zydu Therapeutics INC		Subsidiary Company	Interest Income	N.A.	1										
310	Zydu Pharmaceuticals (USA) Inc.		Nesher Pharmaceuticals (USA) LLC		Subsidiary Company	Loans given	N.A.	56			N.A	N.A	N.A	Loan	USD LIBOR + 54 bps	1 Year	Unsecured	Working Capital
311	Zydu Pharmaceuticals (USA) Inc.		Nesher Pharmaceuticals (USA) LLC		Subsidiary Company	Outstanding Receivables - Loans	N.A.		9,419	9,671								
312	Zydu Pharmaceuticals (USA) Inc.		Sentynl Therapeutics Inc.		Subsidiary Company	Outstanding Receivables - Loans	N.A.		1,041	5,542								
313	Zydu Pharmaceuticals (USA) Inc.		Zydu Noveltech Inc.		Subsidiary Company	Outstanding Receivables - Loans	N.A.		148	184								
314	Zydu Pharmaceuticals (USA) Inc.		Viona Pharmaceuticals INC		Subsidiary Company	Outstanding Receivables - Loans	N.A.		93	284								
315	Zydu Pharmaceuticals (USA) Inc.		ZyVet Animal Health Inc		Subsidiary Company	Outstanding Receivables - Loans	N.A.		115	155								
316	Zydu Pharmaceuticals (USA) Inc.		Zydu Therapeutics INC		Subsidiary Company	Loans given	N.A.	444			N.A	N.A	N.A	Loan	USD LIBOR + 54 bps	3 Years	Unsecured	Business loan
317	Zydu Pharmaceuticals (USA) Inc.		Zydu Therapeutics INC		Subsidiary Company	Outstanding Receivables - Loans	N.A.		37	489								
318	Zydu Pharmaceuticals (USA) Inc.		Zydu Animal Health and Investments Limited		Subsidiary Company	Outstanding Receivables - Other than loans	N.A.		7	8								
319	Zydu Pharmaceuticals (USA) Inc.		Zydu Healthcare (USA) LLC		Subsidiary Company	Outstanding Receivables - Other than loans	N.A.		-	0								
320	Zydu Pharmaceuticals (USA) Inc.		Sentynl Therapeutics Inc.		Subsidiary Company	Outstanding Receivables - Other than loans	N.A.		-	4								
321	Zydu Pharmaceuticals (USA) Inc.		Zydu Noveltech Inc.		Subsidiary Company	Loans given	N.A.	33			N.A	N.A	N.A	Loan	USD LIBOR + 54 bps	1 Year	Unsecured	Working Capital
322	Zydu Pharmaceuticals (USA) Inc.		Hercon Pharmaceuticals LLC		Subsidiary Company	Outstanding Receivables - Other than loans	N.A.		-	2								
323	Zydu Pharmaceuticals (USA) Inc.		ZyVet Animal Health Inc		Subsidiary Company	Loans given	N.A.	37			N.A	N.A	N.A	Loan	USD LIBOR + 54 bps	3 Years	Unsecured	Business loan

Zydus Lifesciences Limited [Formerly Known as Cadila Healthcare Limited]
Disclosure of related party transactions for the half year/ six months ended March 31, 2022

Amount in INR Million except stated otherwise

Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, intercorporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.

S. No.	Details of the party entering into the transaction		Details of the counterparty			Type of Related Party Transaction	Value of the related party transaction as approved by the audit committee	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financials indebtedness is incurred to make or give loans/ investments			Details of loans/ investments				
	Name	PAN [Refer note-1]	Name	PAN [Refer note-1]	Relationship of the counterparty with the listed entity or its subsidiary				Opening balance	Closing balance	Nature of indebtedness [Loans/ issuance of debt/ any other]	Cost of borrowed funds for the listed entity	Tenure	Nature [Loans/ Investments]	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose of the fund utilisation
324	Zydus Pharmaceuticals (USA) Inc.		Zydus Therapeutics INC		Subsidiary Company	Outstanding Receivables - Other than loans	N.A.		-	1								
325	Zydus Healthcare (USA) LLC		Zydus Therapeutics INC		Subsidiary Company	Sale of Services	N.A.	7										
326	Zydus Healthcare (USA) LLC		Zydus Worldwide DMCC		Subsidiary Company	Sale of Services	N.A.	6										
327	Zydus Healthcare (USA) LLC		Zydus Discovery DMCC		Subsidiary Company	Sale of Services	N.A.	0										
328	Zydus Healthcare (USA) LLC		Zydus Pharmaceuticals (USA) Inc.		Subsidiary Company	Sale of Services	N.A.	16										
329	Zydus Healthcare (USA) LLC		Zydus Pharmaceuticals (USA) Inc.		Subsidiary Company	Reimbursement of Expenses Recovered	N.A.	0										
330	Zydus Healthcare (USA) LLC		Zydus Pharmaceuticals (USA) Inc.		Subsidiary Company	Interest Expense	N.A.	6										
331	Zydus Healthcare (USA) LLC		Zydus Pharmaceuticals (USA) Inc.		Subsidiary Company	Outstanding Payables - Loans	N.A.		186	190								
332	Zydus Healthcare (USA) LLC		Zydus Therapeutics INC		Subsidiary Company	Outstanding Receivables - Other than loans	N.A.		1	3								
333	Zydus Healthcare (USA) LLC		Zydus Worldwide DMCC		Subsidiary Company	Outstanding Receivables - Other than loans	N.A.		8	5								
334	ZyVet Animal Health Inc		Zydus Animal Health and Investments Limited		Subsidiary Company	Reimbursement of Expenses Recovered	N.A.	9										
335	ZyVet Animal Health Inc		Zydus Animal Health and Investments Limited		Subsidiary Company	Outstanding Receivables - Other than loans	N.A.		-	9								

Notes:

- As per the guidance note for disclosure of related party transactions dated April 25, 2022, issued by the Stock Exchanges, since the Company is filing the RPT disclosure in PDF format, the PAN details are not to be included in the disclosure.
- Amount mentioned as 0 denotes value less than INR 1 Million.
- The value of the related party transaction denotes the amount approved by the Audit Committee.
- As per approval of Board of Directors or shareholders, as applicable.
- Opening and closing balance are not given where there was no transaction of Investment during the half year ended March 31, 2022.
- Receivables / Payables other than loans represents combined balance against sales / purchase pertaining to goods/ property, plant and equipment / various services / reimbursement of expenses. Hence shown separately.
- Loans given and repaid within reporting period is not disclosed.
- With effect from February 24, 2022, name of the Company has been changed to Zydus Lifesciences Limited from Cadila Healthcare Limited.